Ask Sawal

Discussion Forum
Notification Icon1
Write Answer Icon
Add Question Icon

Lan Thoms




Posted Questions


No Question(s) posted yet!

Posted Answers



Answer


If you think about it, predator hunting is a strange thing to want to do. The hours are terrible. The hunting is tough. Not tough like Chuck Norris or a $3 steak, but tough like trying to understand quantum mechanics or locate the Holy Grail.

After hours of fruitless wailing on a wounded rabbit call, years of bumbling around the winter woods after midnight and coming up empty, it’s only natural to believe there’s some magic formula–some missing bit of super-secret insight–that can transform an average hunter into a predator-calling master. But as the following experts will tell you, consistent success in hunting any predator species comes less from what kind of call or cover scent you use than from a few simple rules and a handful of basic setups that will skew the odds in your favor.

There is no guarantee of success when hunting coyotes – even when you know how to bait coyotes better than anyone else. Most coyote hunting is done after deer season, when every creature in the woods is on edge. Coyotes already live life on a hair trigger. After a typical firearms season, they hit DEFCON One and can become so skittish in some parts of America–especially the East–that you need more luck than skill to dupe one with a predator call. Brian Downs of Cape Cod, Massachusetts, says that now is the time to break out the “baitcicle.”

An Offer They Can’t Refuse Be sure to check the regulations in your state, but for the most part, anywhere biologists value the deer herd, baiting for coyotes is perfectly legal.

“It’s like that movie: If you build it, they will come,” says Downs, who’s been successfully baiting coyotes for more than a decade. He’s written about it, offers seminars on how to do it and often talks about baiting coyotes on his online talkcast (predatortalkcast.com).

In Field of Dreams, Kevin Costner builds a baseball field to draw old ball players to his Iowa farm. Downs makes frozen deer-meat bait piles–baitcicles–and practices what he calls “pressure baiting.”

Most hunters who hunt coyotes over bait do so under a full moon. They wait for a good blanket of snow and suffer through bitter midnight temperatures. By pressure baiting, however, Downs shoots 90 percent of his coyotes in the two hours before dark, just before the temperature plummets.

“For bait, I pack venison scraps into five-gallon buckets, top them off with water and freeze them,” Downs says. Deer processors around his Massachusetts home provide Downs with hundreds of pounds of free meat scraps and bones otherwise bound for the landfill.

According to Downs, who maintains up to 16 bait sites from December through March, successful baiting for coyotes is much like baiting for bears.

It takes a lot of bait and daily visits to a site to not only build the coyotes’ confidence, but also spark a sort of Pavlovian response in them to your comings and goings.

“I don’t care about my scent when I’m putting out bait. I wear the same boots and gloves and run my baits at the same time every day,” explains Downs.

“I want them to associate the smell of my boots with dinner. But each time I visit a site, I put out a little less and a little less, until I’m putting out a softball-size piece of bait. That’s pressure baiting. In the dead of winter, when food is scarce, it makes the coyotes who want to eat come earlier and earlier to the bait site.”   The Setups In a basic setup, you place the bait as close to the coyotes’ bedding area as possible–in the open, but just five steps from cover (A). Downs likes to position himself in an elevated tree stand or a ground blind no less than 75 yards downwind from the bait (B). This keeps him a safe distance away should a cautious coyote choose to circle downwind before committing to the bait.


Answer is posted for the following question.

How to lure in coyotes?

Answer


Warnings and Precautions

Hemorrhage: Fatal bleeding events have occurred in patients who received IMBRUVICA®. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage , gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA® in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA®, respectively.

The mechanism for the bleeding events is not well understood.

Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA® increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA® without antiplatelet or anticoagulant therapy experienced major hemorrhage. The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%. Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA®. Monitor for signs and symptoms of bleeding.

Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections: Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA® therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients who received IMBRUVICA® in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA®. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately.

Cardiac Arrhythmias, Cardiac Failure, and Sudden Death: Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA®. Deaths due to cardiac causes or sudden deaths occurred in 1% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These adverse reactions occurred in patients with and without preexisting hypertension or cardiac comorbidities. Patients with cardiac comorbidities may be at greater risk of these events.

Grade 3 or greater ventricular tachyarrhythmias were reported in 0.2%, Grade 3 or greater atrial fibrillation and atrial flutter were reported in 3.7%, and Grade 3 or greater cardiac failure was reported in 1.3% of 4,896 patients who received IMBRUVICA® in clinical trials, including in patients who received IMBRUVICA® in unapproved monotherapy or combination regimens. These events have occurred particularly in patients with cardiac risk factors including hypertension and diabetes mellitus, a previous history of cardiac arrhythmias, and in patients with acute infections.

Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function. Obtain further evaluation (e.g., ECG, echocardiogram) as indicated for patients who develop symptoms of arrhythmia (e.g., palpitations, lightheadedness, syncope, chest pain), new onset dyspnea, or other cardiovascular concerns. Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA® treatment.

Hypertension: Hypertension occurred in 19% of 1,476 patients who received IMBRUVICA® in clinical trials. Grade 3 or greater hypertension occurred in 8% of patients. Based on data from 1,124 of these patients, the median time to onset was 5.9 months (range, 0.03 to 24 months). Monitor blood pressure in patients treated with IMBRUVICA®, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA® as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension.

Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8% and grade 3 or 4 anemia in 2.8%, based on laboratory measurements. Monitor complete blood counts monthly.

Second Primary Malignancies: Other malignancies (10%), including non-skin carcinomas (3.9%), occurred among the 1,476 patients who received IMBRUVICA® in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%).

Tumor Lysis Syndrome: Tumor lysis syndrome has been infrequently reported with IMBRUVICA®. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate.

Embryo-Fetal Toxicity: Based on findings in animals, IMBRUVICA® can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA® and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during the same time period.

B-cell malignancies: The most common adverse reactions (≥30%) in adult patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%)*, diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%)*, rash (35.8%), anemia (35.0%)*, and bruising (32.0%).

The most common Grade ≥ 3 adverse reactions (≥5%) in adult patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were neutropenia (20.7%)*, thrombocytopenia (13.6%)*, pneumonia (8.2%), and hypertension (8.0%).

Approximately 9% (CLL/SLL), 14% (MCL), 14% (WM) and 10% (MZL) of adult patients had a dose reduction due to adverse reactions. Approximately 4-10% (CLL/SLL), 9% (MCL), and 7% (WM and MZL ) of patients discontinued due to adverse reactions.

cGVHD: The most common adverse reactions (≥20%) in adult or pediatric patients with cGVHD were fatigue (57%), anemia (49%)*, bruising (40%), diarrhea (36%), thrombocytopenia (33%)*, musculoskeletal pain (30%), pyrexia (30%), muscle spasms (29%), stomatitis (29%), hemorrhage (26%), nausea (26%), abdominal pain (23%), pneumonia (23%), and headache (21%).

The most common Grade 3 or higher adverse reactions (≥5%) reported in adult or pediatric patients with cGVHD were pneumonia (14%), anemia (13%)*, fatigue (12%), pyrexia (11%), diarrhea (10%), neutropenia (10%)*, sepsis (10%), osteonecrosis (9%), stomatitis (9%), hypokalemia (7%), headache (5%), and musculoskeletal pain (5%).

Discontinuation of IMBRUVICA® treatment due to an adverse reaction occurred in 24% of adult patients and 23% of pediatric patients. Adverse reactions leading to dose reduction occurred in 26% of adult patients and 19% of pediatric patients.

*Treatment-emergent decreases (all grades) were based on laboratory measurements.

CYP3A Inhibitors: Co-administration of IMBRUVICA® with strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations. Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA® are recommended when used concomitantly with posaconazole, voriconazole, and moderate CYP3A inhibitors. Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA® if strong inhibitors are used short-term (e.g., for ≤ 7 days). Avoid grapefruit and Seville oranges during IMBRUVICA® treatment, as these contain strong or moderate inhibitors of CYP3A. See dose modification guidelines in USPI sections 2.3 and 7.1.

CYP3A Inducers: Avoid coadministration with strong CYP3A inducers.

Pediatric Use: The safety and effectiveness of IMBRUVICA® have not been established for the treatment of cGVHD after failure of one or more lines of therapy in pediatric patients less than 1 year of age. The safety and effectiveness of IMBRUVICA® in pediatric patients have not been established in MCL, CLL/SLL, CLL/SLL with 17p deletion, WM, MZL or in patients with mature B-cell non-Hodgkin lymphoma.

In the randomized population from a study that included 35 patients (26 pediatric patients age 5 to less than 17 years) with previously treated mature B-cell non-Hodgkin lymphoma, major hemorrhage and discontinuation of chemoimmunotherapy due to adverse reactions occurred more frequently in the ibrutinib plus chemoimmunotherapy arm compared to the chemoimmunotherapy alone arm.

Hepatic Impairment:


Answer is posted for the following question.

can imbruvica cause neuropathy?

Answer


  • if (! gr. next()) {
  • alert("You must attach a file to submit.");
  • return false;
  • }
  • }
  • }

Answer is posted for the following question.

How to validate attachment in servicenow?

Answer


Roll the minced meat kofta into small meat balls, put the oven until cooked · In a medium saucepan, heat KDD olive oil, and then add onion, garlic · Add tomato,


Answer is posted for the following question.

How to use kdd bechamel sauce?

Answer


Tahoe & Suburban - 2007 LTZ Polished wheels - Searched to see if this was asked and did not see it - On the new LTZ polished factory wheels ,


Answer is posted for the following question.

How to polish ltz wheels?

Answer


  • Get to know the basics of digital marketing.
  • Start your own website.
  • Become an SEO Expert.
  • Get a Google Ads Certification.
  • Master Facebook Ads Advertising.
  • Become an expert in Google Analytics.
  • Get a digital marketing job as a freelancer.

Answer is posted for the following question.

How to get into digital media?

Answer


  • Communication skills (COM)
  • General self-help ability (SHG)
  • Locomotion skills (LOC)
  • Occupation skills (OCC)
  • Self-direction (SD)
  • Self-help eating (SHE)
  • Self-help dressing (SHD)
  • Socialization skills (SOC)

Answer is posted for the following question.

What is vineland social maturity scale?

Answer


  • From Live View. Right click, select Main Menu.
  • Click Operation.
  • Click System Maintain.
  • Click Default.
  • Click Factory Default.
  • A prompt will appear to confirm the factory default. Click OK.
  • The NVR will default and reboot itself.
  • The unit will boot back up.

Answer is posted for the following question.

How to reset xvr?


Wait...